AngioDynamics Reports Tomorrow But the Guidance Will Matter More Than the Quarter

AngioDynamics (NASDAQ: ANGO) reports fiscal Q3 2026 earnings before market open on April 2, 2026, with analysts expecting a loss of $0.11 per share on revenue of approximately $76.77 million. The medical device company faces a critical test as investors assess whether its minimally invasive vascular and oncology platforms can sustain recent momentum while navigating profitability challenges. With the stock trading at $11.94 and analysts maintaining a bullish stance despite deteriorating sentiment, this report will determine whether ANGO can continue its pattern of beating estimates or if margin pressures will finally catch up.

Part 1: Earnings Preview

AngioDynamics is a medical device company specializing in minimally invasive treatment options for vascular diseases, peripheral interventions, and oncology, with a product portfolio spanning vascular access, thrombectomy, and oncology ablation devices used in hospitals and outpatient facilities globally. The company reports fiscal Q3 2026 results before market open on April 2, 2026, with the consensus calling for a loss of $0.11 per share on revenue of approximately $76.77 million. In the most recently reported quarter (Q2 2026), ANGO posted $0.00 EPS, beating estimates by 100%.

Comparing to the same quarter last year, analysts expect ANGO to report a loss of $0.11 per share versus the prior year's loss of $0.08 per share—representing a 37.5% deterioration year-over-year. This widening loss reflects ongoing investments in growth platforms and operational challenges despite revenue expansion.

Three key themes define this earnings story:

1. Profitability Path and Margin Trajectory: Investors are focused on whether ANGO can demonstrate progress toward profitability after four consecutive quarters of beating estimates. The company's ability to improve gross margins while managing R&D investments in high-growth platforms like AlphaVac and NanoKnife will be critical. Analysts are watching for commentary on adjusted EBITDA trends and the timeline for reaching sustainable profitability.

2. Core Segment Performance and Product Mix: Revenue growth within ANGO's Med Tech and Med Device segments, particularly the balance between recurring consumables revenue and capital equipment sales, will signal the health of the underlying business. Updates on key product launches, regulatory milestones, and adoption rates for advanced technologies will indicate whether the company is gaining market share in its addressable markets.

3. Hospital Purchasing Trends and Supply Chain Stability: With hospital capital budgets under pressure and supply chain dynamics evolving, investors need clarity on customer purchasing patterns, order backlog trends, and any operational headwinds. Management commentary on cash flow generation and working capital efficiency will be essential for assessing near-term financial flexibility.

Analyst commentary ahead of the release emphasizes cautious optimism. While the consensus maintains a bullish stance with an average price target of $19.33 (implying 62% upside from current levels), sentiment has deteriorated over the past month as one analyst downgraded from Strong Buy to Hold. Analysts are particularly focused on whether ANGO can sustain its beat streak while demonstrating tangible progress on the path to profitability, with full-year fiscal 2026 estimates calling for a loss of $0.27 per share compared to the prior year's loss of $0.15 per share.

Part 2: Historical Earnings Performance

AngioDynamics has established a consistent pattern of exceeding analyst expectations, beating estimates in each of the past four quarters. The magnitude of these beats has been substantial: Q2 2026 delivered a 100% surprise ($0.00 actual vs. -$0.10 estimate), Q1 2026 beat by 28.57% (-$0.10 vs. -$0.14), Q4 2025 surprised by 76.92% (-$0.03 vs. -$0.13), and Q3 2025 posted an exceptional 123.08% beat ($0.03 vs. -$0.13 estimate).

The trend reveals improving operational execution, with the company consistently outperforming lowered expectations. Notably, Q3 2025 marked a turning point where ANGO posted positive earnings despite analysts expecting a loss, and Q2 2026 achieved breakeven results when a loss was anticipated. This pattern suggests either conservative analyst modeling or genuine operational improvements that are not yet fully reflected in forward estimates.

However, the year-over-year comparison presents a more nuanced picture. While ANGO beat estimates four quarters ago by reporting $0.03 versus expectations of -$0.13, the current quarter's consensus of -$0.11 represents a deterioration from that prior-year result. This indicates that while the company is beating near-term expectations, the underlying profitability trajectory remains challenged as investments in growth platforms continue to pressure margins.

Note: These figures reflect diluted GAAP earnings per share, reported before non-recurring items, and may differ from the non-GAAP figures used by some sources.

Part 2.1: Price Behavior Around Earnings

AngioDynamics typically reports earnings before market open, meaning Day 0 represents the first full trading session where investors react to results, while Day +1 captures follow-through momentum.

Historical price behavior shows significant volatility around ANGO earnings releases, with an average absolute Day 0 move of 16.42% and Day 0 range of 15.80%. The most recent quarter (October 2025) saw a 6.05% gain on Day 0, while the prior quarter (July 2025) experienced a sharp 10.18% decline despite beating estimates. The pattern reveals that initial reactions can be dramatic in either direction—ranging from a 37.66% surge (January 2025) to a 16.73% drop (October 2024)—suggesting the market is highly sensitive to guidance, margin commentary, and forward outlook rather than just the headline beat or miss.

Day +1 follow-through has been more muted, averaging 4.50% in absolute terms with a 7.77% range, indicating that most of the price discovery occurs in the immediate reaction session. Investors should prepare for potential double-digit percentage swings on earnings day, with the direction heavily dependent on management's commentary around profitability progress and revenue sustainability rather than simply beating the consensus estimate.

Part 2.2: Options Market Expected Move

The options market is pricing an expected move of 12.46% (±$1.49) for the April 17 expiration, which is below the historical average Day 0 move of 16.42% but well within the typical range. This suggests options traders are anticipating meaningful volatility but not the extreme swings seen in some recent quarters, potentially reflecting reduced uncertainty or more stable expectations heading into this release.

Part 3: What Analysts Are Saying

Analysts maintain a bullish stance on AngioDynamics with an average rating of 4.50 (between Buy and Strong Buy), though sentiment has deteriorated over the past month. The current consensus includes 3 Strong Buy ratings and 1 Hold, compared to 4 Strong Buys and 0 Holds a month ago, indicating one analyst has downgraded their recommendation.

The average price target stands at $19.33, implying 62% upside from the current price of $11.94. Price targets range from a low of $16.00 to a high of $24.00, with the high-end estimate suggesting potential for more than doubling from current levels. This wide range reflects differing views on the company's ability to execute on its growth platforms and achieve profitability.

Despite the recent downgrade, the analyst community remains constructive on ANGO's long-term prospects, with the consensus view suggesting the market is undervaluing the company's minimally invasive technology portfolio and addressable market opportunity. However, the shift from unanimous Strong Buy ratings to a mixed outlook signals growing caution about near-term execution risks and the timeline for reaching sustainable profitability. The deteriorating sentiment trend suggests analysts are becoming more selective in their enthusiasm, likely awaiting clearer evidence of margin improvement and revenue acceleration before restoring full conviction.

Part 4: Technical Picture

The Barchart Technical Opinion has strengthened significantly heading into earnings, improving from a Sell signal at 8% one month ago to a Sell signal at 16% last week, and now registering a Buy signal at 24%. This rapid shift reflects building positive momentum as the stock has climbed above key moving averages.

Timeframe Analysis:

• Short-term (Hold): Neutral reading suggests near-term momentum is balanced, with the stock consolidating recent gains
• Medium-term (50% Sell): Moderate sell signal indicates some caution in the intermediate timeframe, reflecting mixed technical indicators
• Long-term (100% Buy): Strong buy signal demonstrates solid longer-term uptrend support and positive structural positioning

Trend Characteristics: The combination of Minimum strength and Average direction suggests the uptrend is in early stages with moderate conviction, indicating the stock is building momentum but has not yet established a powerful directional bias heading into earnings.

ANGO is trading at $11.94, positioned above all major moving averages: the 5-day ($11.27), 10-day ($10.99), 20-day ($10.88), 50-day ($10.85), 100-day ($11.59), and 200-day ($10.91). This alignment above key technical levels provides a supportive backdrop for earnings, though the stock remains below its 100-day average on a relative basis, suggesting some overhead resistance.

The technical setup heading into earnings is cautiously supportive, with the stock trading above most moving averages and showing improving short-term momentum. However, the Minimum strength rating and mixed medium-term signals suggest the uptrend lacks robust conviction. Key resistance likely sits near the $13.43 level (upper end of the options expected move range), while support appears around $10.85 (50-day moving average). Given the historical volatility around ANGO earnings and the current technical positioning, the stock has room to run on positive results but could quickly reverse gains if guidance disappoints or margin concerns resurface. The improving technical opinion provides a tailwind, but investors should remain mindful that the stock's tendency for double-digit percentage moves on earnings day could quickly override near-term technical support levels.